#TANDEM AUTOLOGOUS STEM CELL TRANSPLANT TRIAL#

Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Ladenstein R, Poetschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Risk stratification of high-risk metastatic neuroblastoma: a report from the HR-NBL-1/SIOPEN study. Morgenstern DA, Potschger U, Moreno L, Papadakis V, Owens C, Ash S, et al.

#TANDEM AUTOLOGOUS STEM CELL TRANSPLANT TRIAL#

Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, et al. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. 2015 33:3008–17.Ĭampbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, et al. Advances in risk classification and treatment strategies for neuroblastoma. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al.

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Hence, the patients with MYCN-GA with non-remission status at HDC-autoSCR had a significantly poorer prognosis than the other subgroups, suggesting that HDC-autoSCR may be effective in patients with CR/VGPR regardless of MYCN gene status and in patients with MYCN-NGA regardless of remission status. The interaction between MYCN-GA and ≤PR was significant (p interaction = 0.006). Cumulative hazard curves for neuroblastoma-specific death showed that a subgroup with MYCN-GA and ≤PR had a significantly poorer prognosis than three other subgroups, namely, the MYCN-NGA/ ≤ PR, MYCN-NGA/CR/VGPR, and MYCN-GA/CR/VGPR subgroups even after adjusting for non-infants and stage IV disease (hazard ratio: 2.79 95% confidence interval: 1.91–4.09 P < 0.001). The MYCN status was known in 586 of 950 patients with a single course of HDC-autoSCR. The present study recruited patient data from 1992 to 2017 in the Japan Society of Hematopoietic Cell Transplantation’s national registry. We herein examined the effect modification of high-dose chemotherapy with autologous hematopoietic stem cell rescue (HDC-autoSCR) in terms of the interaction between MYCN status and remission status (complete remission or very good partial remission vs. In high-risk neuroblastoma, the presence of an MYCN gain/amplification (MYCN-GA) is not always a risk factor of cancer-specific death.

Tandem autologous stem cell transplant